The latest Phase II data for Halozyme Therapeutics Inc.'s stromal depleting agent PEGPH20 lend some support for the use of one of the first biomarkers to emerge in pancreatic cancer – hyaluronan – as well as company's Phase III strategy, though the supportive results were not perfect.
The company reported updated results on Jan. 5 from the open-label HALO 202 Phase II study, which evaluated PEGPH20 in...



![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)

